NASDAQ · PHAR
Pharming Group N.V. ADS, each representing 10 financials
$10.01−4.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $376.1M | $297.2M | $245.3M | $205.6M | $198.9M | $212.2M |
| Gross profit | $330.6M | $261.8M | $220.1M | $188.1M | $177.7M | $188.6M |
| Gross margin | 87.9% | 88.1% | 89.7% | 91.5% | 89.4% | 88.9% |
| Operating income | $25.8M | -$8.6M | -$5.4M | $3.7M | $10.9M | $74.4M |
| Net income | $2.9M | -$11.8M | -$10.5M | $13.7M | $16.0M | $37.7M |
| Net margin | 0.8% | −4.0% | −4.3% | 6.7% | 8.0% | 17.8% |
| Diluted EPS | $0.00 | $-0.02 | $-0.02 | $0.02 | $0.02 | $0.06 |
| EBITDA | $37.1M | $7.4M | $10.5M | $16.9M | $30.6M | $82.7M |
| Operating cash flow | $54.7M | -$1.8M | -$17.3M | $22.5M | $37.8M | $83.6M |
| Free cash flow | $54.0M | -$2.6M | -$18.7M | $21.1M | $27.1M | $79.0M |
| Diluted shares | 746.9M | 785.4M | 725.5M | 707.1M | 701.2M | 682.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $145.3M | $54.9M | $61.7M | $207.3M | $191.9M | $205.2M |
| Short-term investments | $33.8M | $112.9M | $151.7M | $0.00 | $0.00 | $0.00 |
| Total debt | $98.1M | $82.4M | $138.4M | $133.4M | $140.9M | $151.8M |
| Total assets | $500.0M | $400.0M | $462.9M | $425.8M | $397.3M | $418.5M |
| Total liabilities | $222.9M | $178.9M | $244.1M | $221.2M | $204.4M | $235.0M |
| Shareholders' equity | $277.1M | $221.1M | $218.8M | $204.6M | $192.9M | $183.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology